Acumen Pharmaceuticals (ABOS) News Today $1.00 -0.04 (-3.85%) Closing price 04:00 PM EasternExtended Trading$1.00 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025May 6 at 4:00 PM | globenewswire.comJPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)JPMorgan Chase & Co. increased its holdings in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 1,387.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 937,908 shares of the company's stock after buying anApril 28, 2025 | marketbeat.comRock Springs Capital Management LP Trims Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Rock Springs Capital Management LP lessened its stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 20.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,838,916 shares of the company's stock after selling 461,143 shares during the period. RocApril 23, 2025 | marketbeat.comFranklin Resources Inc. Has $5.63 Million Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Franklin Resources Inc. lowered its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 7.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,273,633 shares of the company's stock after selling 275,436 shares during the period. FranklApril 13, 2025 | marketbeat.comAcumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trialApril 3, 2025 | markets.businessinsider.comAcumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual MeetingApril 2, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ABOS FY2029 Earnings?Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Acumen Pharmaceuticals in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst A. Fein anticipates that the comMarch 31, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | seekingalpha.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comUBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00UBS Group cut their price objective on Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday.March 29, 2025 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $11.00 at HC WainwrightHC Wainwright lowered their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating for the company in a research note on Friday.March 29, 2025 | marketbeat.comQ4 2024 Acumen Pharmaceuticals Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comAcumen price target lowered to $11 from $15 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)March 29, 2025 | markets.businessinsider.comAcumen Pharmaceuticals’ Earnings Call: Progress Amid ChallengesMarch 28, 2025 | tipranks.comAcumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings ResultsAcumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.15).March 28, 2025 | marketbeat.comAcumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timelineMarch 27, 2025 | msn.comAcumen completes enrollment of ALTITUDE-AD Phase 2 trialMarch 27, 2025 | markets.businessinsider.com1ABOS : Preview: Acumen Pharmaceuticals's EarningsMarch 27, 2025 | benzinga.comAcumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseMarch 26, 2025 | markets.businessinsider.comAcumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 StudyMarch 21, 2025 | nasdaq.comAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025March 20, 2025 | globenewswire.comAcumen Pharmaceuticals at Stifel CNS Days: Alzheimer’s Drug ProgressMarch 20, 2025 | investing.comAcumen announces results from Phase 1 study of sabirnetug in volunteersMarch 20, 2025 | markets.businessinsider.comAcumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy VolunteersMarch 20, 2025 | markets.businessinsider.comAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’sMarch 18, 2025 | finance.yahoo.comAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer'sMarch 18, 2025 | globenewswire.comAcumen Pharmaceuticals (ABOS) Projected to Post Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comAcumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual MeetingMarch 12, 2025 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Down 4% - Here's What HappenedAcumen Pharmaceuticals (NASDAQ:ABOS) Trading Down 4% - Here's WhyMarch 12, 2025 | marketbeat.comAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 10, 2025 | globenewswire.comABOS stock touches 52-week low at $1.31 amid market challengesFebruary 11, 2025 | msn.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 31st total of 1,430,000 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.February 2, 2025 | marketbeat.comABOS stock touches 52-week low at $1.52 amid market challengesJanuary 31, 2025 | msn.comPromising US Penny Stocks To Consider In January 2025January 25, 2025 | finance.yahoo.comAcumen Pharmaceuticals chief medical officer sells $5,118 in sharesJanuary 24, 2025 | msn.comAcumen Pharmaceuticals CFO sells shares totaling $56,619January 24, 2025 | msn.comDaniel Joseph Oconnell Sells 12,619 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockJanuary 24, 2025 | insidertrades.comMatt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 28,902 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the sale, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.January 23, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,619 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total value of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares of the company's stock, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.January 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for ABOS FY2025 EarningsAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the companyJanuary 23, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Growth in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 15th total of 1,430,000 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.January 18, 2025 | marketbeat.comAcumen stock touches 52-week low at $1.54 amid market challengesJanuary 17, 2025 | msn.comAcumen announces Phase 1 INTERCEPT-AD study publicationJanuary 10, 2025 | finance.yahoo.comRussell Barton Sells 7,636 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockJanuary 8, 2025 | insidertrades.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) COO Russell Barton sold 7,636 shares of the business's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.86, for a total value of $14,202.96. Following the transaction, the chief operating officer now owns 89,231 shares in the company, valued at approximately $165,969.66. This trade represents a 7.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider Eric Siemers sold 10,859 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.85, for a total value of $20,089.15. Following the sale, the insider now owns 106,717 shares of the company's stock, valued at $197,426.45. This represents a 9.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 7, 2025 | marketbeat.comMatt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 13,235 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $24,352.40. Following the completion of the transaction, the chief financial officer now owns 198,210 shares of the company's stock, valued at approximately $364,706.40. The trade was a 6.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 47,778 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the transaction, the chief executive officer now owns 454,707 shares in the company, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 5.4% in NovemberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,390,000 shares, a decrease of 5.4% from the November 15th total of 1,470,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 6.9 days. Currently, 3.1% of the shares of the stock are short sold.December 17, 2024 | marketbeat.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.000.69▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼02▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MNPR News Today NVCT News Today CGC News Today FHTX News Today IMMP News Today LFCR News Today CRVS News Today CADL News Today DSGN News Today CDTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABOS Stock Free ABOS Stock Alerts